A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Phase II Clinical Study to Explore the Efficacy and Safety of Different Doses of CMS-D002 Capsule in Participants With Uterine Fibroids Associated With Menorrhagia
Latest Information Update: 18 Feb 2026
At a glance
- Drugs CMS D002 (Primary)
- Indications Menorrhagia
- Focus Therapeutic Use
- Sponsors Shenzhen Kangzhe Pharmaceutical
Most Recent Events
- 18 Feb 2026 New trial record